treatment naļve

Related by string. * TREATMENT . Treatments . TREATMENTS . treatments . Treatment : Water Treatment Plant . Wastewater Treatment Plant . relaxing spa treatments . indulgent Spa Treatments exclusively . Directly Observed Treatment . Point Loma Wastewater Treatment . Botox wrinkle treatment . treatment . sewage treatment . treatment meted . treatment emergent adverse / : naļve * *

Related by context. Frequent words. (Click for all words.) 59 FOLFIRI 58 peginterferon alfa 2a 57 plus prednisone 57 NRTI 57 mcg kg 57 undetectable viral load 57 metastatic renal cell carcinoma 56 plus ribavirin 56 azathioprine 56 dacarbazine 55 HCV infected 55 peginterferon alfa 2b 55 decitabine 55 FOLFOX 55 annualized relapse 55 adalimumab 54 dose cohorts 54 mg BID 54 plus methotrexate 54 IU mL 54 azacitidine 54 copies ml 54 dose escalation trial 54 HCV genotype 1 54 dose regimens 53 #mg dose [003] 53 cytogenetic response 53 ziprasidone 53 median PFS 53 randomized #:# 53 evaluable patients 53 ceftriaxone 53 sustained virologic response 53 chronic HCV infection 53 mitoxantrone 53 atazanavir 53 Median survival 53 confidence interval #.#-#.# 52 severe renal impairment 52 CD4 + cell 52 seroconversion 52 events SAEs 52 peginterferon 52 pg mL 52 Taxotere ® 52 vicriviroc 52 diagnosed multiple myeloma 52 cells/mm3 52 lopinavir 52 ISENTRESS 51 blinded placebo controlled 51 adefovir 51 epoetin alfa 51 mg dose 51 Arch Intern Med 51 peg IFN 51 dose escalation study 51 DMARD 51 Phase 1b clinical 51 HbA1c levels 51 log# 51 lamivudine 51 RECIST criteria 50 CD4 + 50 docetaxel 50 n = 50 CD4 cell 50 copies mL 50 % CI #.#-#.# [006] 50 serum concentrations 49 Phase 2b trial 49 evaluable 49 mg/m2 49 leukopenia 49 Phase 2b study 49 dose escalation 49 Taxotere R 49 gastrointestinal stromal tumors 49 viral loads 49 phase IIa 49 noninferiority 49 febrile neutropenia 49 phase IIb 49 androgen independent 49 PCa 48 castration resistant prostate cancer 48 ± SD 48 Phase 2a trial 48 thromboembolic events 48 neoadjuvant chemotherapy 48 placebo p = 48 multicenter randomized double 48 Phase III randomized 48 J Am Coll 48 blind randomized placebo 48 LVEF 48 confidence interval CI 48 HAART 48 mg d 48 CD4 counts 48 relapsing remitting

Back to home page